Beyond the Wait-and-See: Data-Driven Decision Points for Guiding Selective Serotonin Reuptake Inhibitor Treatment and Cognitive Behavioral Therapy in Pediatric Anxiety Disorders

Abstract

Objectives:

To identify early markers of acute treatment response among youth with anxiety disorders receiving cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitor (SSRI) monotherapy, or their combination.

Background:

Although many youth with anxiety disorders benefit from CBT or SSRIs, response trajectories vary. Identifying early indicators of nonresponse may guide sequencing strategies and improve timely treatment delivery.

Methods:

Using data from the Child/Adolescent Anxiety Multimodal Study, improvement trajectories were modeled for youth (age 7–17) randomized to sertraline monotherapy (N = 133), CBT monotherapy (N = 139), their combination (N = 140), and placebo (N = 76). Patients were stratified by percent change in Pediatric Anxiety Rating Scale (PARS) scores at multiple time points, and logarithmic and logistic time-trend regression models were used to estimate the probability of response. Receiver operating characteristic (ROC) analyses were used to identify thresholds of improvement for predicting response.

Results:

In the sertraline group, ≥25% improvement in PARS score at week 4 had a higher probability of response by week 12 (60.8%) than <25% improvement (31.7%, p = 0.001). In CBT-treated youth, week 4 PARS improvement was less predictive of response, with ≥25% improvement predicting a 47.9% chance of response compared with 28.6% for <25% improvement (p = 0.025). In the combined treatment, ≥25% improvement predicted a73.3% probability of response, whereas <25% improvement yielded a 51.3% likelihood of response (p < 0.001). ROC analyses similarly suggested that week 4 improvement in PARS scores in the CBT group had near equivocal predictive value, though this improved by week 6 to levels comparable to those of the other treatment groups. At week 6, roughly 25% improvement in PARS score in the combined treatment had the best sensitivity and specificity for predicting response.

Conclusions:

Early improvement can predict treatment response in youth with anxiety disorders receiving sertraline monotherapy or combination treatment (sertraline and CBT). Conversely, the absence of early improvement in CBT-treated youth does not reliably predict treatment nonresponse. Treatment-specific thresholds may inform clinical decision making, and support earlier SSRI optimization while allowing more time to observe CBT-related gains.